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See Article, pages 548–556Chronic infection with hepatitis C virus (HCV) is a
huge problem both globally and at the level of the indi-
vidual patient. Part of the problem relates to the fact
that the current standard of care treatment for HCV,
combination pegylated interferon-alpha (PegIFNa)
and ribavirin (Rib), is expensive, associated with signif-
icant side eﬀects, and results in only a 50% rate of sus-
tained virological response (SVR). Predicting the
likelihood of response to treatment prior to initiating
therapy (or soon after starting therapy) would be very
useful [1].
The problem is particularly acute for patients who are
infected with genotype 1 HCV. These patients have a
particularly low SVR rate (in the range of 40–50%) when
compared to more favourable genotypes [2–4], such as
genotypes 2 and 3 (SVR rates of 80–90%). In the patient
population infected with genotype 1 HCV, there are
really no pre-treatment predictors of the response to
therapy that are robust enough to warrant denying an
individual patient combination therapy. There are also
few accepted pre-treatment factors that strongly encour-
age treatment.
In addition to viral and patients characteristics, the
genetic diversity of the host contributes to the outcome
of infection and treatment of chronic HCV. In the cur-
rent issue of the Journal, Morgan et al. [5] present the0168-8278/$34.00  2008 European Association for the Study of the Liver.
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reported to be associated with either response to inter-
feron-based therapy or with the risk of ﬁbrosis develop-
ment, in a sub-population of patients participating in
the Hepatitis C anti-viral Long-term Treatment against
Cirrhosis (HALT-C) trial. These patients, non-Hispanic
Caucasians with genotype 1 HCV infection, achieved
SVR following treatment with PegIFNa/Rib. Eight sin-
gle nucleotide poymorphisms (SNPs) previously
reported to be associated with treatment response were
assessed by polymerase chain reaction-based assays.
The presence of any single SNP was not associated with
SVR; however, SVR was more common among the
patients who were homozygous for the ACC variant
IL-10 promoter diplotype (OR, 3.24; p = 0.001).
How HCV, IFN and the host interact at a molecular
level is being studied in many contexts, and there is an
expanding body of literature that seeks to deﬁne this
complex interplay in a clinically useful way. Several
groups have used microarray-based approaches and
have reported distinct subgroups of genes whose expres-
sion level varies between treatment responders and non-
responders. For example, we identiﬁed a discrete set of
18 genes whose pre-treatment hepatic expression levels
diﬀerentiated between responders and non-responders
[6]. Many of these genes were IFN sensitive genes
(ISGs), and three of them (USP18/UBP43, CEB1, and
ISG15) play roles in the same IFN regulatory pathway,
suggesting a possible rationale for treatment resistance.
These results have now been substantiated by other
groups [7,8], and have been validated prospectively in
a larger cohort of chronic HCV patients prior to initiat-
ing anti-viral treatment [9]. Subsequently a two-gene
signature (IF127 and CXCL9) was identiﬁed by AsselahPublished by Elsevier B.V. All rights reserved.
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patients that can accurately predict treatment response
in 79% of patients being treated for HCV [8]. Both genes
are ISGs and are upregulated in the liver biopsies of
treatment non-responders. In another microarray-based
study, Feld et al. conﬁrmed that pretreatment ISG
expression is higher in the pre-treatment liver tissue of
slow responders than in the liver tissue of rapid respond-
ers [7]. After 72 h of treatment with PegIFNa/RBV
there was little further upregulation of ISG expression
in the liver tissue of non-responders, while ISG expres-
sion was strongly induced in the liver tissue of rapid
responders. For reasons that are unclear, pre-treatment
ISG upregulation fails to clear the virus in non-respond-
ers, but the upregulation of the same ISGs in rapid
responders when treated with PegIFNa/Rib is associ-
ated with viral clearance. The response to treatment in
circulating blood cells is also diﬀerent in responders
and non-responders: ISG upregulation in the peripheral
mononuclear blood cells of treatment non-responders is
relatively blunted when compared to treatment respond-
ers [10,11]. Host predispositions likely play a fundamen-
tal role in this altered regulation of IFN-sensitive
pathways.
The Morgan et al. [5] study looks at genetic polymor-
phisms, speciﬁcally single nucleotide polymorphisms
(SNPs) that might play a role in this intriguing dys-reg-
ulation of components of the anti-viral response that
inﬂuences HCV treatment response. Prior to this study
SNPs have been analyzed both for prediction of HCV
disease progression [12] and therapeutic response
[13,14]. Genes that have been assessed by SNP analysis
including those for ISGs with anti-viral activity such
as 2-5oligoadenylate synthetase (2-5 OAS), dsRNA acti-
vated protein kinase (PKR) and MxA protein. Several
studies have reported an association between treatment
response and SNPs in the promoter regions of MxA,
OAS-1 and PKR [13,15,16]. While it is diﬃcult to draw
ﬁrm conclusions from these relatively small studies, it is
interesting that both OAS and MxA were found to be
associated with treatment response in our group’s
impartial gene expression proﬁling study [6].
SNPs speciﬁc to cytokines, chemokines and their
receptors have also been examined for associations with
the results of anti-HCV treatment [14,17,18]. One of the
cytokines examined is IFN-c, which is produced by
eﬀector T and natural killer cells and has a critical role
in the host defense against a variety of intracellular
pathogens, including HCV. IFN-c eﬃciently inhibits
HCV replication in the replicon system in vitro [19],
and intrahepatic levels of IFN-c appear to be associated
with viral clearance in the chimpanzee model [20]. In a
recent study of two patient cohorts, Huang et al. demon-
strated an important role between a speciﬁc polymor-
phism of IFN-c and treatment response [21]. The ﬁrst
cohort included 280 chronic HCV patients who hadreceived INFa-based therapy. The second cohort con-
tained 250 IV drug abusers who either spontaneously
cleared the virus or became chronically infected. The
authors demonstrated that among the eight analyzed
SNPs spanning the entire IFN-c gene in the two cohorts,
only one SNP variant (-764G, located in the proximal I
IFN-c promoter region) was signiﬁcantly associated
with sustained virological response in the ﬁrst cohort
and with spontaneous recovery in the second cohort.
A number of studies have examined other cytokines,
such as IL-10, in a manner analogous to Morgan et al.
[5] IL-10 is a potent anti-inﬂammatory Th2 cytokine
that down-regulates the expression of major histocom-
patibility complex (MHC) class 1 and class II molecules
as well as the production of Th1 cytokines [22,23]. IL-10
levels diﬀer widely between individuals, possibly due to
polymorphisms in the promoter region of the IL-10
genes [24]. High serum levels of IL-10 have been corre-
lated with poor response to interferon therapy, whereas
IL-10 production has been found to be lower in
responders than in non-responders [25]. Speciﬁcally, 3
SNPs in the promoter (at positions-1082, -819, and -
592 relative to the transcription start site) form 3 combi-
nations (ATA, ACC, GCC) which are associated with
diﬀerential IL-10 expression [25,26]. Yee et al. examined
whether polymorphisms in the IL-10 promotor region
might play a role in the outcome of anti-viral therapy
[27]. Their relationship to the outcome of anti-viral ther-
apy for chronic HCV infection was studied in 49 Cauca-
sian patients with SVR and in 55 non-responders. The
presence of the -592A or -819T alleles; the -592A/A or
-819T/T genotypes; the combination of (-592A)–(-
819T)/ (-592A)–(-819T) as a genotype; or the extended
(108) TCATA haplotype was signiﬁcantly associated
with an SVR. However, after stratiﬁcation for viral
genotype, baseline viral RNA concentration, and histol-
ogy status, homozygosity for the (108) TCATA haplo-
type was found to be the principal determinant for
SVR (OR crude = 13.7; p = 0.025) of SVR to INF/Rib
[27].
The overall results from previous studies of how IL-
10 haplotype and/or individual Il-10 promoter poly-
morphisms are associated with the HCV response to
IFN-based treatment are inconsistent. The Morgan
et al. [5] study sheds more light on the intriguing
and complex association between host genetics varia-
tions and response to treatment by analyzing a larger
cohort of patients. The large size of the study popula-
tion, uniform treatment regimen and close follow-up
are key considerations when interpreting the presented
data.
However, some of the inclusion criteria related to the
initial design of the HALT C trial could inﬂuence Mor-
gan et al.’s ﬁndings. One obvious concern is the enroll-
ment of only non-responder patients to anti-viral
therapy – this likely eliminates the more favorable
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Although the authors argue that despite exclusion from
the therapy of naı¨ve patients, they were able to replicate
the reported risk factor for treatment failure in previous
studies with untreated patients, it is possible that one
reason that the current study did not conﬁrm any of
the previous SNP associations was the exclusion of
treatment-naı¨ve genotype 1 patients. The exclusion of
treatment responders does complicate the generalization
of Morgan et al.’s ﬁndings, but does not detract from
the overall worth of the data.
Clearly, the challenge faced by all studies on the asso-
ciations of gene polymorphism and drug eﬃcacy/
response is the complexity of the interacting factors con-
tributing to variable drug responses. These include
numerous genes (often dozens) signaling molecules and
multiple environmental factors [28,29]. One of the great-
est challenges for the future is understanding how these
factors contribute to drug response in the individual
patient with HCV. Only large cohort studies, such as
the work by Morgan et al., have the power to face this
challenge, but even larger studies are needed. In our
opinion, the path forward is to pool data from individ-
ual investigators and groups, and the marked improve-
ments in the consistency of genomics-type data should
permit this.
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